Cancer treatment reports 1987-05-01

Phase I study of two schedules of teroxirone.

J Rubin, J S Kovach, M M Ames, C G Moertel, E T Creagan, M J O'Connell

Index: Cancer Treat. Rep. 71(5) , 489-92, (1987)

Full Text: HTML

Abstract

Two schedules of teroxirone, a triazine triepoxide, were evaluated in a phase I study. Twenty-six patients were treated on 1 day every 5 weeks at doses of 36-2250 mg/m2. At doses greater than or equal to 1500 mg/m2, severe thrombophlebitis was seen without cytotoxic effect, and this schedule was closed. Twenty-seven patients were treated on 5 days every 5 weeks at daily doses of 16-450 mg/m2. Mild thrombophlebitis and moderate leukopenia were encountered. For phase II studies, a dose of 375 mg/m2 X 5 every 5 weeks is recommended. Pharmacologic studies showed rapid plasma elimination, which suggests the agent's possible usefulness for regional infusion.